Business Context and Reporting Period
This Form 8-K filing by Collegium Pharmaceutical, Inc. (the "Company") reports on events occurring on June 4, 2018. The Company is an emerging growth company incorporated in Virginia. The report details significant changes in executive leadership and associated compensatory arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and executive compensation.
Material Changes
- Executive Leadership Transition: Joseph Ciaffoni, previously Executive Vice President and Chief Operating Officer, was appointed President and Chief Executive Officer (CEO), effective July 1, 2018. He will also serve as a Class II member of the Board of Directors.
- CEO Resignation: Michael T. Heffernan resigned as President and CEO effective June 30, 2018. He will continue to serve as Chairman of the Board.
- Compensation Policy Update: The Non-Employee Directors' Compensation Policy was amended to include an additional annual retainer of $60,000 for the Chairman of the Board.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding the Company's business operations or market conditions. The primary commentary relates to the qualifications of the new CEO, Mr. Ciaffoni, citing his extensive experience in the pharmaceutical industry with companies such as Endo International, Biogen Idec, Shionogi, and Novartis.
Compensatory Arrangements
- Mr. Ciaffoni (New CEO):
- Base salary: $600,000.
- Target annual bonus: 60% of base salary.
- Equity Grant: Options and Restricted Stock Units (RSUs) each valued at approximately $625,000, vesting over four years.
- Severance: Enhanced benefits including 150% of annual base salary and target bonus in the event of termination without cause or resignation for good reason within 12 months of a change in control.
- Mr. Heffernan (Outgoing CEO):
- Pro rata annual bonus through June 30, 2018.
- Waiver of COBRA premiums for up to 18 months and payment of annual family deductible.
- Accelerated vesting of all outstanding unvested equity awards at the 2020 annual meeting, contingent on continued Board service.
- Compensation as a non-employee director.
Important Facts for Investor Verification
- Verify the effective dates of the leadership transition (July 1, 2018 for Ciaffoni; June 30, 2018 for Heffernan).
- Review the attached Exhibit 10.1 (Employment Amendment) and Exhibit 10.2 (Letter Agreement) for full legal terms regarding severance and equity vesting.
- Confirm the total equity value granted to Mr. Ciaffoni ($1.25 million combined in options and RSUs) and its impact on dilution.
- Note that the filing does not provide updated financial results; investors should refer to the most recent 10-K or 10-Q for financial health.